Final report of the phase i trial of the hypoxic cell radiosensitizer SR 2508 (etanidazole) radiation therapy oncology group 83-03

This publication has 18 references indexed in Scilit:

• Initial results of a phase i trial of continuous infusion SR 2508 (etanidazole): A radiation therapy oncology group study
  International Journal of Radiation Oncology*Biology*Physics, 1989
• Chemical modifiers of cancer treatment.
  Journal of Clinical Oncology, 1988
• Phase I trial of the hypoxic cell radiosensitizer SR-2508: The results of the five to six week drug schedule
  International Journal of Radiation Oncology*Biology*Physics, 1986
• Chemical sensitizers for hypoxic cells: A decade of experience in clinical radiotherapy
  Radiotherapy and Oncology, 1985
• Hypoxic cell radiosensitizers: Expectations and progress in drug development
  International Journal of Radiation Oncology*Biology*Physics, 1985
• Initial report of the phase I trial of the hypoxic cell radiosensitizer SR-2508
  International Journal of Radiation Oncology*Biology*Physics, 1984
• Clinical trials of radiosensitizers: What should we expect?
  International Journal of Radiation Oncology*Biology*Physics, 1984
• The potential benefit from a perfect radiosensitizer and its dependence on reoxygenation
  The British Journal of Radiology, 1982
• SR-2508: A 2-nitroimidazole amide which should be superior to misonidazole as a radiosensitizer for clinical use
  International Journal of Radiation Oncology*Biology*Physics, 1981
• Misonidazole in fractionated radiotherapy: are many small fractions best?
  The British Journal of Radiology, 1980